ArticleJournal of the American Society of Nephrology : JASN2016
B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.
Article in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07702981 (Immunophenotyping Profiling in Patients With Nephrotic Syndrome), which is not on this map. Cited by 130 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunophenotyping Profiling in Patients With Nephrotic Syndrome: Emphasis on the Diagnostic and Prognostic Value of Immune Cells in the Different Phenotypes of Nephrotic Syndrome.
Who cites it
130 citing papers in PubMed, 2 syntheses or guidelines pooled it, 213 citations in OpenAlex.
- Current status and research hotspots of pediatric nephrotic syndrome: a bibliometric analysis (2011-2025).Frontiers in pediatrics · 2026Pooled it
- The efficacy of rituximab in the treatment of refractory nephrotic syndrome: a meta-analysis.International urology and nephrology · 2020Pooled it
- CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.Frontiers in immunology · 2021Trial
- Hypogammaglobulinemia and B cell repopulation after rituximab in childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Peripheral B-cell receptor immunoglobulin heavy chain repertoire as a potential biomarker for frequently relapsing nephrotic syndrome in children.Renal failure · 2026Article
- B-cell-targeting therapies in podocytopathies.Pediatric nephrology (Berlin, Germany) · 2026Review
- Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Single-cell transcriptomic signatures of T cells associated with rituximab responsiveness in idiopathic nephrotic syndrome.iScience · 2026Article
- Pursuing the optimal strategy for immunosuppression discontinuation in children treated with rituximab for frequently relapsing, steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Complete remission after rituximab therapy of pemphigus: Real-world evidence on dosing regimens and retreatment strategies.JID innovations : skin science from molecules to population health · 2026Article
- Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy.International journal of molecular sciences · 2026Review
- Anti-CD20 Therapies and Antinephrin Autoantibodies in IgA Nephropathy With Minimal Change Disease.Kidney international reports · 2026Article
- Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy.Kidney international reports · 2026Article
- Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report.World journal of nephrology · 2026Article
- [Characterization of Immune Reconstitution Patterns in B-cell Subsets Mediated by B-cell Targeted Therapies].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- The safety of rituximab in pediatric nephrotic syndrome patients: a pharmacovigilance study of the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Anti-CD20 monoclonal antibodies for idiopathic nephrotic syndrome: Advances, challenges, and future directions.Pediatric nephrology (Berlin, Germany) · 2025Article
- Targeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- T-cell and autoantibody profiling for primary immune regulatory disorders.The Journal of allergy and clinical immunology · 2025Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byBusy Bs.2016
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of nephrotic syndrome is unclear. However, the efficacy of rituximab, a B cell-depleting antibody, in nephrotic syndrome suggests a pathogenic role of B cells. In this retrospective study, we determined by flow cytometry levels of B and T cell subpopulations before and after rituximab infusion in 28 pediatric patients with frequently relapsing or steroid-dependent nephrotic syndrome. At baseline, patients had lower median percentages of transitional and mature B cells than age-matched healthy controls (P<0.001). Rituximab induced full depletion of B cells (<1% of lymphocytes). At 1 year, most patients exhibited complete total and mature B cell recovery, whereas memory B cell subsets remained significantly depleted. Total T cell concentration did not change with rituximab, whereas the CD4(+)/CD8(+) T cell ratio tended to increase. Fourteen patients relapsed within 24 months, with a median follow-up of 11.2 months (interquartile range, 8-17.7 months). We observed no difference at baseline between nonrelapsing and relapsing patients in several clinical parameters and cell subset concentrations. Reconstitution of all memory B cell subpopulations, number of immunosuppressive drugs, and dose of tacrolimus during the last 4 months of follow-up were predictive of relapse in univariate Cox regression analysis. However, only delayed reconstitution of switched memory B cells, independent of immunosuppressive treatment, was protective against relapse in multivariate (P<0.01) and receiver operator characteristic (P<0.01 for percentage of lymphocytes; P=0.02 for absolute count) analyses. Evaluation of switched memory B cell recovery after rituximab may be useful for predicting relapse in patients with nephrotic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.